Clinical Trials Logo

Genotype 1 Chronic Hepatitis C clinical trials

View clinical trials related to Genotype 1 Chronic Hepatitis C.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01498068 Completed - Clinical trials for Genotype 1 Chronic Hepatitis C

Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis C

Start date: January 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the effectiveness, safety and tolerability of telaprevir administered as 750 mg every 8 hours (q8h) in combination with pegylated interferon (Peg-IFN)-alfa-2a and ribavirin (RBV) in treatment-naïve and treatment-experienced Russian participants with genotype 1 chronic hepatitis C.

NCT ID: NCT01241760 Completed - Clinical trials for Genotype 1 Chronic Hepatitis C

VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection

Start date: December 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effectiveness of telaprevir administered twice daily versus every 8 hours in combination with Peg-IFN-alfa-2a and ribavirin in treatment-naïve participants with chronic HCV genotype 1 infection.

NCT ID: NCT00606086 Completed - Clinical trials for Genotype 1 Chronic Hepatitis C

Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection

Start date: December 2007
Phase: Phase 2
Study type: Interventional

The GI-5005 therapeutic vaccine in combination with standard of care or standard of care alone will be injected under the skin of HCV subjects. Patients will be monitored for safety, immune responses and any therapeutic benefits related to the injections including EVR, ETR, and SVR.